What is LadRx's earnings per share (EPS)?

LadRx (LADX) reported diluted earnings per share of $-3.21 for fiscal year 2024. This represents a -572.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

LadRx Financials

LADX

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2025 Currency USD FYE December

This page shows LadRx (LADX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LADX FY2024 2026-04-22

Cash depletion, not leverage expansion, is driving the story as fixed overhead consumes a rapidly shrinking balance sheet.

FY2023’s reported profit of $400K sat beside a core operating loss of $3.8M, so the apparent turnaround did not come from a self-supporting operating model. That becomes clearer in FY2024, when net income fell to -$1.6M while operating cash flow swung to -$1.3M; the business still depended on items outside normal operations to look healthier in the prior year.

Liquidity tightened fast: cash fell to $760K and the current ratio slipped to 0.4x, which means near-term obligations outweighed the liquid assets available to meet them. Against FY2024 operating cash burn of $1.3M, that balance covered well under a year of activity unless financing arrived or spending fell materially.

Balance-sheet erosion came more from asset depletion than fresh borrowing: total liabilities were roughly steady at $2.3M while total assets fell to $840K. That pushed equity further negative, showing the recent deterioration was driven mainly by consuming cash and other assets rather than by a large new liability build.

Financial Health Signals

Financial Profile 17/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of LadRx's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

LadRx has elevated debt relative to equity (D/E of -1.59), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

LadRx's current ratio of 0.37 is below the typical benchmark, resulting in a score of 2/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

2/9

LadRx passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.82x

For every $1 of reported earnings, LadRx generates $0.82 in operating cash flow (-$1.3M OCF vs -$1.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$3.6M

YoY+5.1%

LadRx's EBITDA was -$3.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.1% from the prior year.

Net Income

-$1.6M

YoY-497.0%

LadRx reported -$1.6M in net income in fiscal year 2024. This represents a decrease of 497.0% from the prior year.

EPS (Diluted)

$-3.21

YoY-572.1%

LadRx earned $-3.21 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 572.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$760K

YoY-63.3%

5Y CAGR-45.7%

10Y CAGR-31.3%

LadRx held $760K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

495,092

YoY+0.0%

LadRx had 495,092 shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$773K

YoY+176.5%

5Y CAGR+13.9%

10Y CAGR-32.0%

LadRx invested $773K in research and development in fiscal year 2024. This represents an increase of 176.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

LADX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$773K+176.5%	$279K	N/A	N/A	$800K+98.4%	$403K
SG&A Expenses	$2.8M-19.5%	$3.5M-22.3%	$4.5M-23.8%	$6.0M-0.6%	$6.0M-19.3%	$7.4M
Operating Income	-$3.6M+5.2%	-$3.8M+16.2%	-$4.6M+62.2%	-$12.1M-76.8%	-$6.8M+13.1%	-$7.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	$8000.0%	$800
Net Income	-$1.6M-497.0%	$400K+109.5%	-$4.2M+68.1%	-$13.2M-96.6%	-$6.7M+6.5%	-$7.2M
EPS (Diluted)	$-3.21-572.1%	$0.68+718.2%	$-0.11	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$29K	N/A	$4K-99.2%	$594K+1859.9%	$30K	N/A	$15K	N/A
SG&A Expenses	$691K	N/A	N/A	$701K-12.6%	$802K	N/A	$826K-19.1%	$1.0M
Operating Income	-$720K	N/A	N/A	-$1.3M-55.6%	-$832K	N/A	-$840K+17.7%	-$1.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$719K	N/A	N/A	-$1.3M-787.1%	$187K	N/A	-$816K-125.9%	$3.1M
EPS (Diluted)	$-1.45	N/A	$-1.67+35.5%	$-2.59-781.6%	$0.38	N/A	$-1.65-125.6%	$6.45

LADX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$840K-63.6%	$2.3M+2.7%	$2.2M-74.3%	$8.7M-27.6%	$12.1M-30.1%	$17.3M
Current Assets	$837K-63.0%	$2.3M+12.9%	$2.0M-75.8%	$8.3M-27.5%	$11.4M-33.6%	$17.2M
Cash & Equivalents	$760K-63.3%	$2.1M+50.6%	$1.4M-79.7%	$6.8M-32.3%	$10.0M-38.0%	$16.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M+2.7%	$2.2M-38.3%	$3.6M-55.3%	$8.0M+150.0%	$3.2M+55.6%	$2.1M
Current Liabilities	$2.3M+2.7%	$2.2M+0.6%	$2.2M-41.4%	$3.7M+34.6%	$2.8M+35.3%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.4M-1422.2%	$107K+108.1%	-$1.3M-274.9%	$754K-91.5%	$8.9M-41.7%	$15.2M
Retained Earnings	-$490.1M-0.3%	-$488.5M+0.1%	-$488.8M-1.0%	-$484.1M-2.8%	-$470.7M-1.4%	-$464.0M

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Total Assets	$260K-69.0%	$840K+1028.8%	$74K-91.7%	$894K-59.8%	$2.2M-3.8%	$2.3M-24.7%	$3.1M-23.0%	$4.0M
Current Assets	$258K-69.1%	$837K+1082.0%	$71K-92.0%	$889K-59.9%	$2.2M-2.1%	$2.3M-23.8%	$3.0M-22.6%	$3.8M
Cash & Equivalents	$207K-72.8%	$760K+1226.9%	$57K-93.0%	$817K-60.4%	$2.1M-0.3%	$2.1M-29.4%	$2.9M-18.6%	$3.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M+6.0%	$2.3M+23.5%	$1.8M+0.1%	$1.8M-2.6%	$1.9M-14.7%	$2.2M+4.8%	$2.1M-4.6%	$2.2M
Current Liabilities	$2.4M+6.0%	$2.3M+23.5%	$1.8M+0.1%	$1.8M-2.6%	$1.9M-14.7%	$2.2M+4.8%	$2.1M-4.6%	$2.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.1M-50.4%	-$1.4M+19.1%	-$1.8M-87.9%	-$934K-370.5%	$345K+221.6%	$107K-88.9%	$965K-45.8%	$1.8M
Retained Earnings	-$490.8M-0.1%	-$490.1M+0.1%	-$490.4M-0.2%	-$489.6M-0.3%	-$488.3M0.0%	-$488.5M-0.2%	-$487.6M-0.2%	-$486.8M

LADX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$1.3M-229.2%	$1.0M+121.0%	-$4.8M+60.7%	-$12.3M-100.5%	-$6.1M-7.4%	-$5.7M
Capital Expenditures	N/A	N/A	$766-89.1%	$7K-73.0%	$26K+5.0%	$25K
Free Cash Flow	N/A	N/A	-$4.8M+60.8%	-$12.3M-99.7%	-$6.2M-7.4%	-$5.7M
Investing Cash Flow	N/A	N/A	-$766+89.1%	-$7K+73.0%	-$26K-105.4%	$475K
Financing Cash Flow	N/A	-$319K+43.2%	-$561K-106.2%	$9.1M+23187.5%	$39K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Operating Cash Flow	-$553K-178.7%	$702K	N/A	-$1.2M-21103.7%	-$6K+99.3%	-$863K-28.9%	-$670K-120.6%	$3.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0+100.0%	-$250K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LADX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	373.0%	N/A	-1748.2%-1672.7pp	-75.5%-28.4pp	-47.1%
Return on Assets	-189.4%-206.7pp	17.3%+204.3pp	-187.0%-36.0pp	-151.0%-95.4pp	-55.6%-14.0pp	-41.5%
Current Ratio	0.37-0.7	1.03+0.1	0.92-1.3	2.22-1.9	4.12-4.3	8.39
Debt-to-Equity	-1.59-22.1	20.50+23.2	-2.70-13.3	10.58+10.2	0.36+0.2	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	54.1%	N/A	-84.5%-261.3pp	176.8%
Return on Assets	-276.6%	N/A	N/A	-143.5%-151.9pp	8.4%	N/A	-26.6%-105.7pp	79.1%
Current Ratio	0.11-0.3	0.37+0.3	0.04-0.4	0.49-0.7	1.18+0.2	1.03-0.4	1.41-0.3	1.74
Debt-to-Equity	-1.12+0.5	-1.59-0.5	-1.04+0.9	-1.96-7.4	5.43-15.1	20.50+18.3	2.18+0.9	1.24
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.37), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Lobe Sciences LOBEF

$27.6M

AIBotics AIBT

$624K

Therapeutic Solutions Intl Inc TSOI

$512K

Bio-Path Hldgs Inc BPTH

$4.7M

Emmaus Life Scie EMMA

$809K

Frequently Asked Questions

Is LadRx profitable?

No, LadRx (LADX) reported a net income of -$1.6M in fiscal year 2024.

What is LadRx's EBITDA?

LadRx (LADX) had EBITDA of -$3.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is LadRx's operating cash flow?

LadRx (LADX) generated -$1.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are LadRx's total assets?

LadRx (LADX) had $840K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does LadRx spend on research and development?

LadRx (LADX) invested $773K in research and development during fiscal year 2024.

How many shares does LadRx have outstanding?

LadRx (LADX) had 495,092 shares outstanding as of fiscal year 2024.

What is LadRx's current ratio?

LadRx (LADX) had a current ratio of 0.37 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is LadRx's debt-to-equity ratio?

LadRx (LADX) had a debt-to-equity ratio of -1.59 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is LadRx's return on assets (ROA)?

LadRx (LADX) had a return on assets of -189.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is LadRx's cash runway?

Based on fiscal year 2024 data, LadRx (LADX) had $760K in cash against an annual operating cash burn of $1.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is LadRx's debt-to-equity ratio negative or unusual?

LadRx (LADX) has negative shareholder equity of -$1.4M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is LadRx's Piotroski F-Score?

LadRx (LADX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are LadRx's earnings high quality?

LadRx (LADX) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is LadRx?

LadRx (LADX) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.